(Press-News.org) Estybon® (ON 01910.Na) is a small molecule, targeted therapeutic with a broad spectrum of activity. It has been tested in patients with solid tumors, myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) at major centers in the U.S. and abroad. MDS and AML are blood disorders widely recognized as difficult to manage, with limited therapeutic options for patients, especially those with drug-resistant disease. The presentations will describe the latest results on activity and safety of Estybon® (ON 01910.Na) in MDS and AML patients treated in on-going Phase I and Phase II clinical trials.
These studies are a part of comprehensive evaluation of the safety and activity of Estybon® (ON 01910.Na). To date, nearly 300 cancer patients have been treated in Phase I and Phase II trials, including more than 70 patients with MDS or AML. These studies have lead to a multi-site Phase III pivotal trial under a Special Protocol Assessment (SPA) from the U.S. FDA. This trial is being supported by an award from the Therapeutics Acceleration Program (TAP) of the Leukemia and Lymphoma Society (LLS).
"We continue to make meaningful progress in our MDS program, and information to be presented at the ASH meeting reflects the breadth of data becoming available for ON 01910.Na in MDS patients," said Francois Wilhelm, MD, PhD, Senior Vice President and Chief Medical Officer of Onconova. "We are committed to the rapid development of this promising agent for MDS patients by conducting a multi-site trial in the United States and France," Dr. Wilhelm added.
Another presentation will highlight the mechanism of action and activity in nonclinical models of mantle cell lymphoma (MCL) of ON 013105, a novel Onconova agent directed to controlling Cyclin D1 in cancer cells (Abstract #771). ON 013105 alone or in combination with rituximab induced dramatic reduction of MCL tumor volumes in mouse xenograft models, suggesting that ON 013105 alone or in combination may be a potent therapeutic agent against MCL. ON 013105 is currently in Phase I clinical safety studies in lymphoma patients.
###
About ESTYBON
Estybon® (ON 01910.Na), is a small molecule inhibitor of critical pathways important in the growth and proliferation of cancer cells. Extensive Phase I and Phase II studies with Estybon® have been conducted in patients with solid tumors and hematological cancers, including MDS and AML, where more than 70 patients have been enrolled in studies conducted at four leading institutions in the U.S. FDA has granted Orphan Drug Designation for the use of Estybon® in MDS. A U.S. Patent covering ON 01910.Na issued in October 2009 and international patent coverage is expected.
About Onconova Therapeutics, Inc.
Onconova, based in Newtown, PA and Princeton, NJ, discovers and develops novel small molecule therapeutics with fully differentiated targets involved in signal transduction, cell-cycle, and DNA repair. These candidates are derived from a proprietary library of new chemical entities and non-ATP competitive chemotypes. In addition to Estybon® (ON 01910.Na) and ON 013105, Onconova is also developing Ex-RAD®, an injectable and oral radioprotectant. The oncology preclinical pipeline at Onconova includes inhibitors of Plk2, ALK, CDK, JAK, and Bcr-Abl pathways and a novel immunoconjugate platform for arming therapeutic antibodies. Currently, Onconova is conducting clinical trials at major centers in the U.S. and abroad for three product candidates. For additional information, please visit http://www.onconova.com.
Summary of ASH Presentations Relating to Estybon® (ON 01910.Na) and ON 013105
Sunday, December 5:
Session: Myelodysplastic Syndromes Poster II, Hall A3/A4 (Orange County Convention Center)
Poster Board # II-824
Abstract #2944
"Evaluation of ON 01910.Na in Patients with a Myelodysplastic Syndrome (MDS) or Acute
Myeloid Leukemia (AML) Relapsed or Refractory to Hypomethylating Agents: A Phase I Study"
Lewis R Silverman, Shyamala C. Navada, Rosalie Odchimar-Reissig, Vesna Najfeld, Takao Ohnuma, Francois Wilhelm, E. Premkumar Reddy, James F. Holland; Division of Hematology/Oncology, Mount Sinai School of Medicine, New York, NY; Mount Sinai School of Medicine, New York, NY; Onconova Therapeutics, Inc., Newtown, PA
Monday, December 6:
Session: Myelodysplastic Syndromes Poster III, Hall A3/A4 (Orange County Convention Center)
Poster Board # III-777
Abstract #3998
"Overall Survival in Patients with a Myelodysplastic Syndrome or Acute Myeloid Leukemia Treated With ON 01910.Na Correlates with Bone Marrow Blast Response"
Lewis R. Silverman, Azra Raza, Elaine Sloand, Peter L. Greenberg, Francois Wilhelm; Mount Sinai Medical Center, New York, NY, Columbia University Medical Center, New York, NY, National Heart, Lung and Blood Institute, Bethesda, MD, Stanford University Cancer Center, Stanford, CA, Onconova Therapeutics, Inc., Newtown, PA
Poster Board # III-789
Abstract #4010
"Treatment of Higher Risk Myelodysplastic Syndrome Patients Unresponsive to Hypomethylating Agents with ON 01910.Na"
Mahesh Seetharam, Mai Tran, Alice C. Fan, Liwen Xu, John P. Renschler, Dean W. Felsher, Kunju Sridhar, Francois Wilhelm, Peter L. Greenberg; Departments of Medicine (Hematology) and Medicine (Oncology), Stanford University Cancer Center, Stanford, CA;, Onconova Therapeutics Inc., Newtown, PA
Session: Lymphoma/Pre-Clinical/Chemotherapy and Biologic Agents: Preclinical Advances in Mantle Cell Lymphoma (Oral Presentations); Session Time 4:30 - 6:00 PM; Room 308 (Orange County Convention Center)
Presentation Time: 5:00 PM
Abstract #771
"Synergistic Effects of a Novel Water-soluble Small Molecule, ON 013105, and Rituximab on Mantle Cell Lymphoma In vitro and In vivo"
Anil Prasad, Ashutosh Shrivastava, Ramana MV Reddy, Amanda Gillum, E. Premkumar Kumar Reddy, Jerome Groopman: Division of Experimental Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; Department of Oncological Sciences, Mount Sinai School of Medicine, New York, NY, Onconova Therapeutics, Inc., Newtown, PA
END
Astronomers have traced the waxing and waning light of exploding stars more closely than ever before and seen patterns that aren't yet accounted for in our current understanding of how these eruptions occur.
Using data from a sensitive instrument aboard a satellite that images the entire sky every 102 minutes, they studied four of these stars, or novae, that exploded so violently their light would have been visible without a telescope and measured their brightness over the course of the outburst.
Three of the novae stalled before reaching a peak, and all flickered or ...
GO Markets is pleased to announce the upgrade and replacement of their servers to a new state of the art technology. In light of the growing need for faster and more efficient systems, GO Markets have made the investment and move to a dedicated rack server system. Paul Hill - Managing Director of GO Markets commented on the upgrade and what it would mean for clients.
"...We believe in providing our clients with the most up to date and efficient systems available. The new state of the art HP hardware, will allow for faster processing time, and ultimately faster execution, ...
Since its incorporation in December 2003, Magnoware has been innovating in help desk technology through web-enabled work order and ticket tracking, Active Directory integration, network & workstation auditing and email-to-ticket conversion. The company now services clients from all over the world in a diverse range of industries, including bakeries, video game developers, educational institutions, telecommunications firms and more.
The DataTrack System is a powerful service and support management system designed for helpdesks, call centers, software development teams ...
Your Time with Josie, an internet radio show and podcast broadcasting live every Friday evening with 15 year old host Josie Passantino, has reached it's first milestone with it's first anniversary, plus, a nomination for the 6th annual Podcast Awards for entertainment (voting udnerway, winners announced mid-December).
With 60 episodes and counting, and previous guests such as Katie Cook, Steven Dorff, Susie McEntire, Savannah Outen, and a slew of others, the listener base and follows has grown considerably over the past year, espcailly on social networks such as Twitter ...
Zetta Worldwide Technologies has announced the release of Accredicom, a new healthcare accreditation software service. This new revolutionary software is a web-based software solution that simplifies the accreditation process for healthcare providers looking to earn and maintain national certification.
In a time when the healthcare industry faces many new challenges from new healthcare laws, Accredicom allows medical professionals to simplify the certification process. Getting a new business accredited can be a daunting task, but the new software makes the certification ...
Department of Computer and Information Sciences, University of Strathclyde and Associates. The introduction of smartcard technologies has reduced the incidence of card fraud in the UK, but there are still significant losses from fraudulent
card use. In this paper we detail the context of smartcard introduction and describe
the types of fraud that remain a threat to cardholders and other stakeholders
in the card system. We conclude with a risk analysis from the cardholder's
perspective and recommend greater cardholder awareness of such
risks.
A recent report from ...
The new release, available from today, builds on Yellowfin's renowned ease-of-use reporting and analytics solution, offering users social media style features to improve information collaboration.
"Yellowfin 5.1 furthers Yellowfin's mandate to make Business Intelligence easy by introducing a raft of new features to improve organization-wide knowledge sharing, providing a crucial bridge between insight and action," said Yellowfin CEO, Glen Rabie.
The release, and its social and collaborative components, received strong endorsement from BI industry veteran, Ian Nicholson.
"When ...
In an effort to educate Americans on dental implants Dr. Miller of Caring Dentistry is offering tips on how to spot dental problems.
"Most people know to see their doctor when they have a high fever," notes Dr. Tim Miller, DDS. "However, for some reason many Americans do not see their dentist when they have a dental worry. Part of this is because dental issues are not always easy to identify, and people who are not dental professionals do not realize the severity of the problem. To help you stay on top of your dental health, we have put together the following list of ...
To help show their support for the Canadian troops, Shirley and Bruce MacNaughton, owners of the Prince Edward Island Preserve Company, are now offering a special package for deployed military personnel through the Preserve Company's online store.
There are two gift boxes available: one contains three 250ml jars of preserves and one contains six. The boxes have special labels with messages of support in the design. The Preserve Company will donate $5 from the smaller package and $10 from the larger one to the PEI Military Family Services Centre, an organization helping ...
SBCoupons.com has launched as Santa Barbara's top coupon destination - a place where locals and visitors go to save money on everything from restaurants, to shopping, and even services. SBCoupons.com features numerous and diverse deals with coupons from local merchants in Santa Barbara and the surrounding communities of Goleta, Montecito, Summerland, and Carpinteria. Santa Barbara locals, as well as visitors traveling to Santa Barbara from all over the world, can now visit http://www.SBCoupons.com and receive free coupons. No signup is required, and users of SBCoupons.com ...
